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Abstract
Background: Clinical heterogeneity can be defined as differences in participant characteristics, types or timing of
outcome measurements and intervention characteristics. Clinical heterogeneity in systematic reviews has the possibility to
significantly affect statistical heterogeneity leading to inaccurate conclusions and misled decision making. The aim of this
study is to identify to what extent investigators are assessing clinical heterogeneity in both Cochrane and non-Cochrane
systematic reviews.
Methods: The most recent 100 systematic reviews from the top five journals in medicine—JAMA, Archives of
Internal Medicine, British Medical Journal, The Lancet, and PLOS Medicine—and the 100 most recently published
and/or updated systematic reviews from Cochrane were collected. Various defined items of clinical heterogeneity were
extracted from the included reviews. Investigators used chi-squared tests, logarithmic modeling and linear regressions to
determine if the presence of such items served as a predictor for clinical heterogeneity when comparing Cochrane to
non-Cochrane reviews. Extracted variables include number of studies, number of participants, presence of quantitative
synthesis, exploration of clinical heterogeneity, heterogeneous characteristics explored, basis and methods used
for investigating clinical heterogeneity, plotting/visual aids, author contact, inferences from clinical heterogeneity
investigation, reporting assessment, and the presence of a priori or post-hoc analysis.
Results: A total of 317 systematic reviews were considered, of which 199 were in the final analysis. A total of 81 % of
Cochrane reviews and 90 % of non-Cochrane reviews explored characteristics that are considered aspects of clinical
heterogeneity and also described the methods they planned to use to investigate the influence of those characteristics.
Only 1 % of non-Cochrane reviews and 8 % of Cochrane reviews explored the clinical characteristics they initially chose
as potential for clinical heterogeneity. Very few studies mentioned clinician training, compliance, brand, co-interventions,
dose route, ethnicity, prognostic markers and psychosocial variables as covariates to investigate as potentially
clinically heterogeneous. Addressing aspects of clinical heterogeneity was not different between Cochrane and
non-Cochrane reviews.
Conclusions: The ability to quantify and compare the clinical differences of trials within a meta-analysis is crucial
to determining its applicability and use in clinical practice. Despite Cochrane Collaboration emphasis on methodology,
the proportion of reviews that assess clinical heterogeneity is less than those of non-Cochrane reviews. Our
assessment reveals that there is room for improvement in assessing clinical heterogeneity in both Cochrane
and non-Cochrane reviews.
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Background
Systematic reviews often apply statistical techniques to
combine data, a meta-analysis, in order to arrive at a
pooled treatment effect. However, the precision of this
estimate depends on heterogeneity within and between
the included studies. Clinical heterogeneity can be de-
fined as differences in participant characteristics (e.g.,
age, baseline disease severity, ethnicity, comorbidities),
types or timing of outcome measurements and interven-
tion characteristics (e.g., dose, frequency of dose, train-
ing of interventionists) [1]. Clinical heterogeneity can
cause significant statistical heterogeneity leading to in-
accurate conclusions and ultimately misled decision
making [1].
Healthcare professionals and policy makers are not
commonly using systematic reviews as decision-making
references despite their valuable applications [2]. Never-
theless, by teasing out factors that may influence the
outcome effect, clinical heterogeneity assessment pro-
vides clinical decision makers with not only a more reli-
able estimate of the treatment effect, but also ideally the
ability to tailor their interventions to improve the health
outcomes of their patients.
Clinical heterogeneity is not to be confused with statis-
tical heterogeneity or methodological heterogeneity. While
clinical heterogeneity is the difference in intervention and
outcome measurement, statistical heterogeneity is differ-
ences in results when measuring the same outcome [1].
This may include both opposite findings (benefit versus
harm) or simply a difference in the extent of benefit or
harm across studies. Ironically, it is possible that statistical
heterogeneity could be a product of the presence of
clinical or methodological heterogeneity. However, it is
important to note that the lack of statistical heterogeneity
should not preclude the investigation of either clinical or
methodological heterogeneity.
There is no lack of resources offering reviewers routes
to investigate statistical heterogeneity in systematic re-
views. However, across consensus-based guidelines, statis-
tical papers, and expert narrative reviews, there is little
overlap in recommendations and only a small number of
sources include a comprehensive set of recommendations
regarding clinical heterogeneity [3]. Of nine methods
manuals of the organizations or public-sector agencies
that produce the largest number of systematic reviews,
only five— U.S. Agency for Healthcare Research and
Quality, Evidence-based Practice Centers Program (AHRQ
EPC Program); Centre for Reviews and Dissemination
(CRD); Cochrane Collaboration; Oregon Health & Science
University Drug Effectiveness Review Project (DERP);
European Network for Health Technology Assessment
(EUnetHTA)—provided definitions of clinical hetero-
geneity, of which Cochrane provides the most detailed
discussion [4]. Cochrane Handbook defines the three
types of heterogeneity, explains how they differ, and
offers advice regarding forest plots, a priori subgroup
analysis and meta-regression to assess clinical hetero-
geneity [1]. Thus, the aim of this study is to identify to
what extent investigators are assessing clinical hetero-




The most recent 100 systematic reviews published in
2012 were collected from five of the top journals in
medicine as determined by impact factors as listed in
the 2011 Thompson ISI citation reports of General and
Internal Medicine: Journal of American Medical Associ-
ation (JAMA), Archives of Internal Medicine (AIM), British
Medical Journal (BMJ), The Lancet, and PLOS Medicine.
To note, due to its limited number of annual systematic
review publications, New England Journal of Medicine
(NEJM) was not included in this study despite its high
impact factor. Additionally, investigators retrieved the 100
most recently modified systematic reviews from the
Cochrane Database published in 2012. A total of 317 of
the most recently updated/published papers were ini-
tially considered for inclusion, however studies were
excluded because they were only updated abstracts, au-
thor name changes or shortened versions of previously
published reviews. Papers included were reported as
being systematic reviews or meta-analyses only from
any field of medicine.
Data Extraction
Investigators extracted data relating to number of studies
included, total number of participants (i.e., the sample size
across all included studies in each review), expertise of the
review team members (by referring to their degrees/
training and to relevant information on web pages at
their respective institutions), presence of quantitative
synthesis, exploration of clinical heterogeneity, clinically
heterogeneous characteristics explored, basis for exploring
clinical heterogeneity, methods used in investigating
clinical heterogeneity, plotting and visual aids, author
contact, inferences from clinical heterogeneity investi-
gation, reporting assessment, and a priori vs. post-hoc
analysis (Table 1) [5]. All data were extracted by one in-
dividual (LC) and cross-checked by an experienced
methodologist and physician (JG).
Statistical Analyses
Investigators conducted a chi-squared comparison of
Cochrane versus non-Cochrane studies regarding number
of studies included, total number of participants, presence
of quantitative synthesis, exploration of clinical heterogen-
eity, clinically heterogeneous characteristics explored, basis
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Table 1 Criteria for investigating clinical heterogeneity in systematic reviews [5]
Review team It is recommended to have at least one or two individuals with clinical expertise, and at least one
or two individuals with methodological expertise in systematic reviews/meta-analyses and on the
type of study designs that are included.
The team should recognize their own biases and attempt to compensate by including members
with a wide range of (potentially conflicting) beliefs.
Quantitative synthesis Did the review perform a quantitative synthesis?
Clinical heterogeneity variables Did the authors choose characteristics for exploring that can be considered aspects of "clinical
heterogeneity"?
Patient level: Age, baseline disease severity, sex, gender, ethnicity, comorbidities,
genetic, otherpsychosocial variables, and other important features of the disease.
Intervention level: Dose/strength/intensity of treatment, duration of treatment, brand/manufacturer,
cointerventions, timing, route of administration, compliance, clinician training, implementation, other.
Outcome level: Event type, outcome measure type, outcome definition, length of follow-up, timing
of outcome measurement(s).
Other: Research setting, geographical issues, length of follow-up.
Planned clinical heterogeneity exploration Did the authors describe how they planned to investigate differences between studies?
All investigations of clinical heterogeneity should ideally be pre-planned a priori and not be driven
by observing the data. But methods for looking at data to identify unanticipated variables of
interest (i.e., post-hoc investigations) need to be pre-specified as well (e.g., looking at summary
tables, graphical displays). Describe the following: which variables you will investigate, how this
will be done, when you will perform these investigations, and how results will be interpreted and
incorporated into your results and conclusions.
A priori vs. post-hoc Was it a priori or post-hoc?
Reviewers should think through all potentially relevant variables to explore and not rely on statistical
measures of heterogeneity to justify such investigations.
Individual patient data (IPD) vs. aggregate
patient data (APD)
Was IPD, APD or a combination used?
APD = Summary or aggregate data from trials only. This is subject to ecological bias, that is, investigations
of trial-level variables are valid (e.g., dose, duration), while investigations of patient-level variables are not
(e.g., age, baseline severity).
IPD = Original individual data on each patient. This type of data is valid for both trial-level and
patient-level variables. But, one must control for baseline difference between the patients across
trials. Consider contacting authors and reviewing protocols of primary studies where available.
Obtaining IPD for investigating clinically related patient-level variables is ideal.
Parsimony—number of investigations to
perform and variables to explore
Was parsimony used in choosing variables to explore?Use parsimony as a guide to such
investigations. A rule of thumb for the number of trials is that there should be close to ten trials
when working with summary or aggregate patient data (APD) or ten individuals per variable,
when working with pooled or individual patient data (IPD). Consider making a hierarchy of
clinically related variables and investigate only those variables for which your rationale and power
are sufficient.
Clinical heterogeneity variables not
later investigated
Were there characteristics that were chosen that were not eventually investigated?
Variables that were mentioned to potentially contribute to clinical heterogeneity which were
ultimately never investigated (or reported) in the analysis.
Outliers/sensitivity analysis When there are individual trials that are clear outliers, was there an attempt to determine why?
(e.g., was a sensitivity analysis done, where these trials are eliminated and effect estimate
changes?
When there are individual trials that are clear outliers, attempt to determine why and
consider asensitivity analysis to eliminate these trials and observe how the effect estimate
changes. One may also consider an influence analysis, in which the effect of deleting individual
studies from the analysis on the overall estimate is explored.
Statistical heterogeneity Was statistical heterogeneity assessed?
Statistical heterogeneity as prerequisite to
investigate clinical heterogeneity
Was statistical heterogeneity used as a prerequisite for investigating clinical variables?Reviewers
should think through all potentially relevant variables to explore and not rely on statistical
measures of heterogeneity to justify such investigations. Clinical heterogeneity related to specific
individual factors could be present even in the absence of a significant statistical test for the
presence of heterogeneity (e.g., Cochran’s Q test)
Plots/visuals Were plotting or other visual aids used to explore reasons for clinical heterogeneity?
Consider using graphical displays of data from trials to help identify potential clinical reasons
for heterogeneity. Examples of plotting and visual aids of the data include: summary data sheets,
forest plots, L’Abbé plots, funnel plots, Galbraith plots/radial plots, influence plots, dose/response
curves, multidimensional scaling, and heat maps.
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for exploring clinical heterogeneity, methods used in inves-
tigating clinical heterogeneity, plotting and visual aids,
author contact, inferences from clinical heterogeneity inves-
tigation, reporting assessment, and a priori vs. post-hoc
analysis (Table 2). Investigators performed logistic regres-
sion with Cochrane or non-Cochrane systematic reviews
being the response variable and the aforementioned
components of clinical heterogeneity investigations being
the predictors (Table 3) followed by a deletion process
(Table 4).
Results
A total of 317 systematic reviews were considered, of
which 199 were in the final analysis. The topics of
Cochrane and non-Cochrane reviews differed with ques-
tions related to musculoskeletal, pulmonary and repro-
ductive areas and non-Cochrane reviews more often
relating to cardiac, endocrine and other medical condi-
tions (see Fig. 1). Overall, the assessment and measure-
ment of clinical heterogeneity varied greatly. A total of
81 % of Cochrane reviews and 90 % of non-Cochrane re-
views explored characteristics that are considered as-
pects of clinical heterogeneity and also described the
methods they planned to use to investigate the influence
of those characteristics. The most commonly mentioned
variables were age, sex, comorbidities, setting, geographic
location, severity of disease and dose/dosing frequency.
Unfortunately, only 1 % of non-Cochrane reviews and 8 %
of Cochrane reviews explored all those clinical character-
istics they initially chose. Additionally, very few studies
mentioned clinician training, compliance, brand, co-
interventions, dose route, ethnicity, prognostic markers
and psychosocial variables as co-variates to investigate
as potentially clinically heterogeneous.
Table 1 Criteria for investigating clinical heterogeneity in systematic reviews [5] (Continued)
Cautious inferences Was caution used in making inferences from the findings of investigations of heterogeneity?
Results are generally observational and thus hypothesis generating only. Authors should express the
validity of and confidence in their findings. When interpreting results of these investigations it is
suggested to consider: confounding, other sources of bias (e.g., publication, misclassification, dilution,
selection), magnitude and direction of effect and CI, and thinking through the plausibility of causal
relationships. It may not be appropriate to conclude that there is consistency of effect if subgroup
effects are not found [20]. Authors should use their findings to make specific recommendations
about how future research could proceed or build upon these results (not just conclude that “more
research is needed”).
Sufficient reporting When there was insufficient information, were the study authors contacted for more information?
Reporting at a limitation Was the reporting in the included studies assessed and commented on as a potential problem for
investigating clinical heterogeneity?
Consider the potential for lack of reporting of data or information relating to clinical variables in the
primary studies. Consider contacting the authors for missing or additional data on important clinical
variables. Reviewers must be careful to report all of their proposed and actual investigations of clinical
heterogeneity. The PRISMA statement should be adhered to when reporting their reviews.
Table 2 Chi-squared analysis of Cochrane status by individual item scores
N, % = yes (Cochrane) N, % = yes (Non-Cochrane) p value
Review team 1 (1.0) 5 (5.1) 0.091
Quantitative synthesis 63 (63.0) 81 (81.8) 0.0030
CH variables 90 (90.0) 80 (80.8) 0.066
Planned CH exploration 89 (89.0) 73 (73.7) 0.0057
A priori vs. post-hoc 11 (11.0) 34 (34.3) <0.0001
Parsimony 65 (65.0) 93 (93.9) <0.0001
CH not investigated 56 (56.0) 29 (29.3) 0.0001
Outliers/sensitivity 40 (40.0) 50 (50.5) 0.14
Proper reporting 84 (84.0) 42 (42.4) <0.0001
Statistical hetero-geneity (SH) 74 (74.0) 85 (85.9) 0.037
SH used for investigating CH 2 (2.0) 2 (2.0) 0.38
Plots/visual aids 20 (20.0) 11 (11.1) 0.084
Cautious inferences 68 (68.0) 86 (86.9) 0.0015
Reporting as limitation 30 (30.0) 22 (22.2) 0.20
CH clinical heterogeneity
Bolded p value indicates significance
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In regards to comprehensive heterogeneity assessment,
several measured areas of analysis in both Cochrane and
non-Cochrane reviews were lacking. Only 49 % of non-
Cochrane and 40 % of Cochrane reviews performed a
sensitivity analysis to assess for outliers. Cochrane reviews
(83 %) were however much better than non-Cochrane re-
views (41 %) at contacting authors regarding missing data.
In forming and describing an appropriate team for
sufficient planning and analysis, only 5 % and 2 % of all
systematic reviews reported having researchers with
methodological expertise in non-Cochrane and Cochrane
reviews, respectively. Regarding data analysis, 81 % of
non-Cochrane reviews included a meta-analysis compared
to 62 % of Cochrane reviews. The majority of reviews
made general suggestions regarding the importance of
aspects relating to clinical heterogeneity but did not dis-
cuss the impact of these aspects on their analysis.
Another important aspect to assessing clinical hetero-
geneity is the transparency and truthful reporting of
heterogeneity assessment and inferences. Arguably, limited
reporting was a chief impediment to assessing the clinical
heterogeneity analysis of these systematic reviews. How-
ever, only 22 % of non-Cochrane and 30 % of Cochrane
reviews acknowledged reporting as a problem for investi-
gating clinical heterogeneity.
A chi-squared test of the proportional percentage of
“yes” for item scores showed that authors were more
likely to describe how they planned to investigate clinical
heterogeneity in Cochrane reviews, even though they
were less likely to have performed a quantitative synthe-
sis (Table 2). Additionally, chi-squared analysis revealed
statistical favoritism towards non-Cochrane studies in
performing a parsimonious and a priori analysis, as well
as assessing statistical heterogeneity. However, Cochrane
reviews also had proportionally increased contact with
study authors if there was insufficient reporting. Lastly, a
greater proportion of non-Cochrane reviews showed
caution in making inferences from the findings of inves-
tigations of heterogeneity while Cochrane reviews were
more likely to have characteristics that were chosen but
not eventually investigated (Table 2).
From the logistic regression modeling, when comparing
Cochrane and non-Cochrane studies, quantitative synthe-
sis (OR = 0.38, CI = 0.20–0.73), greater number of studies
(OR = 0.94, CI = 0.92–0.97) and aggregate patient data
(OR = 0.28, CI = 0.15–0.53) were more likely to be in-
cluded in the non-Cochrane systematic review (Table 3).
Addressing aspects of clinical heterogeneity was not a sig-
nificant predictor of whether the study was of Cochrane or
non-Cochrane origin (OR = 2.14, CI = 0.94-4.87, p = 0.070).
Discussion
Inevitably, studies in systematic reviews will differ to
varying extents. How these differences are identified and
assessed influences the overall value of a systematic re-
view. Our assessment reveals that there is room for im-
provement in assessing clinical heterogeneity in both
Cochrane and non-Cochrane reviews. Despite Cochrane
Table 3 Logistic regression for being a Cochrane Review (dependent/response variable) by various predictor variables
OR 95 % CI p value
Number of studies 0.94 0.92–0.97 <0.0001
Number of participants (log) 0.14 0.077–0.24 <0.0001
Quantitative synthesis (1 = yes, 0 = no) 0.38 0.20–0.73 0.0035
Individual patient data (IPD; 1 = yes, 0 = no)* n/a n/a
Aggregate patient data (APD; 1 = yes, 0 = no) 0.28 0.15–0.53 0.0001
Combination of IPD & APD (1 = yes, 0 = no) 1.00 0.24–4.11 1.00
Investigated an aspect of clinical heterogeneity (1 = yes, 0 = no) 2.14 0.94–4.87 0.070
Note: 1. Bolded p value indicates significance. 2. OR of greater than 1 favors being a Cochrane Review for each variable
*No Cochrane studies conducted individual patient data analysis
Table 4 Logistic regression with stepwise deletion for being a Cochrane Review (dependent/response variable) by various predictor
variables
Model 1 (OR, p value) Model 2 (OR, p value)
Number of studies 0.96, 0.0011 0.96, 0.0015
Number of participants 1.00, 0.025 1.00, 0.025
Quantitative synthesis (1 = yes, 0 = no) 0.087, 0.0014 0.12, 0.0006
APD 1 = yes, 0 = no) 1.48, 0.51
Combination of IPD and APD (1 = yes, 0 = no) 12.9, 0.054 8.72, 0.066
Investigated an aspect of clinical heterogeneity (1 = yes, 0 = no) 5.29, 0.016 5.08, 0.019
Note: 1. Bolded p value indicates significance. 2. OR of greater than 1 favors being a Cochrane Review
Chess and Gagnier BMC Medical Research Methodology  (2016) 16:19 Page 5 of 7
Collaboration emphasis on methodology, the proportion
of reviews that assess clinical heterogeneity is less than
those of non-Cochrane reviews. It is suggested that re-
viewers would benefit from a clear set of universal
guidelines as to how to assess clinical heterogeneity.
More problematic is that clinical heterogeneity is diffi-
cult to measure because of a lack of reporting, poorly
described interventions and incomplete details of partici-
pant characteristics. One of the strengths of this study is
its search of recently published reviews from across vari-
ous medical arenas. This may also mean a difference in
journal reviewer emphasis on reporting clinical hetero-
geneity. However, it is important to note that this study
included the 100 most recently published systematic re-
views in selected journals and is largely not a compre-
hensive search of all reviews across all areas of medicine.
Several of the reviews we investigated did not have
enough information to properly determine if and how
well they assessed clinical heterogeneity. While reporting
is a common problem, there are no universal guidelines
on assessing clinical heterogeneity. This lack of educa-
tion is ultimately impeding the ability to accurately de-
termine a review’s generalizability and could result in
drastically skewed treatment effect estimates. It is im-
portant to note that a lack of complete reporting does
not necessarily imply poor assessment. Thus in addition
to investigating the methods of clinical heterogeneity, it
is important that authors and reviewers ensure the clear
and complete reporting of such assessments.
There are several potential limitations to our study.
First, we included only 200 systematic reviews that
were published in 2012. Therefore, our results may not
generalize to other years, to other journals or to other
Cochrane reviews. Second, data were extracted by one
individual and cross-checked by an experienced statistician
and physician. Ideally, all data would be independently ex-
tracted by two reviewers and compared to avoid bias. Next,
we did not account for details of the instructions to au-
thors in these journals. That is, the journals included in
our study may have variable reporting or method guide-
lines for systematic reviews (e.g., PRISMA guidelines) [6].
Thus, published reviews in these journals will be influ-
enced by such guidance, resulting in different assessments
of clinical heterogeneity and ultimately of these reviews.
Future research in this area could review the instructions
to authors to determine their potential influence on inves-
tigations of clinical heterogeneity.
Measuring clinical heterogeneity requires some planning.
We recommend investigators pre-plan what variables they
want to investigate and discuss why they chose those vari-
ables. This may entail soliciting experts in the discipline to
recommend what variables they feel are important to
clinical decision-making. This might include inviting coin-
vestigators who have clinical or content expertise on the
specific question or topic of the review. Additionally, inves-
tigators should decide which method to use to determine
the effects of those variables (i.e., plots, contacting authors,
statistical procedures, etc.). It is important to decide upon
these criteria before data analysis and state in the meta-
analysis that they did so. The planning team should
consist ideally of at least two individuals—one with
clinical expertise and one with expertise in systematic
Fig. 1 Selected Cochrane and non-Cochrane studies arranged by discipline
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reviews or meta-analyses. As before, this team should
be acknowledged, described, and critiqued in the methods
section of the review.
In addition, we recommend investigators perform a
post-hoc analysis. This may include looking at summary
data sheets, looking at forest plots from meta-analyses
and/or utilizing L’Abbe plots, dose–response curves, fun-
nel plots, Galbraith plots and influence plots. After iden-
tifying all the variables of interest (both pre-planned and
post-hoc), authors should have ideally at least 10 trials
per variable to ensure power [7, 8]. To explore these vari-
ables, investigators should employ the use of subgroup
analyses and/or meta-regressions. This should be followed
up with sensitivity analyses to test the robustness of find-
ings relative to decisions made in the review process. The
method and reporting of investigating clinical heterogeneity
should be transparent and propose future investigations to
improve on implemented methods. In particular, we rec-
ommend that systematic reviews closely follow reporting
guidelines for systematic reviews (PRISMA) [6] and recent
guidance for investigating clinical heterogeneity [5].
Conclusions
In summary, defining the clinical characteristics that in-
fluence the intervention helps to tease out what population
would most benefit from the intervention, or conversely
who would be most harmed by that intervention. It is
advised that all systematic reviews assess clinical variables
and consider potential sources of heterogeneity via analysis,
visual aids and with the help of individuals with methodo-
logical expertise in systematic reviews.
Abbreviations
AHRQ EPC Program: U.S. Agency for Healthcare Research and Quality,
Evidence-based Practice Centers Program; CRD: Centre for Reviews and
Dissemination; DERP: Oregon Health & Science University Drug Effectiveness
Review Project; EUnetHTA: European Network for Health Technology Assessment.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LC performed the data collection, manuscript writing and analysis.
JG conceptualized the project, performed the data analysis, wrote and
revised the manuscript. Both authors read and approved the final manuscript.
Author details
1Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA.
2Department of Orthopaedic Surgery, University of Michigan, Ann Arbor
MI, USA. 3Epidemiology, School of Public Health, University of Michigan, Ann
Arbor, MI, USA.
Received: 16 July 2015 Accepted: 9 February 2016
References
1. Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of
Interventions. Version 5.0.1 [updated September 2008]. The Cochrane
Collaboration, 2008. Accessed at: www.cochrane-handbook.org.
2. Laupacis A, Straus S. Systematic reviews: Time to address clinical and policy
relevance as well as methodological rigor. Ann Int Med. 2007;147(4):273–5.
3. Gagnier JJ, Moher D, Boon H, Beyene J, Bombardier C. Investigating clinical
heterogeneity in systematic reviews: a methodologic review of guidance in
the literature. BMC Med Res Methodol. 2012;12:111.
4. West SL, Gartlehner G, Mansfield AJ, Poole C, Tant E, Lenfestey N, Lux LJ,
Amoozegar J, Morton SC, Carey TC, Viswanathan M, Lohr KN: Comparative
Effectiveness Review Methods: Clinical Heterogeneity [Internet]. Rockville,
MD: Agency for Healthcare Research and Quality (US); 2010 Sep. 3, Results.
Available from: http://www.ncbi.nlm.nih.gov/books/NBK53317/
5. Gagnier JJ, Morgenstern H, Altman DG, Berlin J, Chang S, McCulloch P, et al.
Consensus-based recommendations for investigating clinical heterogeneity
in systematic reviews. BMC Med Res Methodol. 2013;13:106.
6. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group: Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. PLoS Med. 2009;6(7), e1000097.
7. Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of
Interventions. Version 5.1.0 [updated March 2011]. The Cochrane
Collaboration, 2011. Accessed at: www.cochrane-handbook.org.
8. Altman DG. Practical statistics for medical research. London: Chapman &
Hall/CRC; 1991.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chess and Gagnier BMC Medical Research Methodology  (2016) 16:19 Page 7 of 7
